



APPOINTMENT OF ALISTAIR BENNALLACK TO BOARD OF DIRECTORS

MELBOURNE (AUSTRALIA) 26 October 2020: Invion Limited (ASX: IVX) ("Invion" or the "Company") is pleased to announce the appointment of Alistair Bennallack as a Non-Executive Director with effect from 22 October 2020.

Mr Bennallack has over 30 years' experience in business management and finance, strategic development, risk and compliance, international business, leadership and relationship management.

Mr Bennallack is currently the Chief Executive Officer of Village Roadshow Theme Parks Asia and Head of Risk at Village Roadshow Ltd with the primary executive responsibility for conceptualising, executing and delivering Village Roadshow's expansion into China and Asia.

He is a former member of the Village Roadshow Ltd Executive Committee, current member of the Village Roadshow Theme Parks Executive Committee and current member of all Village Roadshow Ltd's Management and Risk Committees.

His previous roles have included Chief Financial Officer of Village Roadshow Ltd and General Manager Business Affairs of Village Roadshow Corporation Pty Ltd (controlling shareholder of Village Roadshow Ltd).

Mr Bennallack is a member of the Institute of Chartered Accountants in Australia and has a Graduate Diploma in Wine Business. He is also the former President and Board Member of The Gawler Foundation.

"I am very pleased to be able to announce a tremendous addition to the Board of Invion," commented Mr Thian Chew, Chairman of Invion.

"Alistair's addition to the Board broadens the depth of management and commercial experience at the Board table."

Investor and Media enquiries:

Thian Chew (Chairman)

T: +61 3 9692 7222

E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)

T: 0409 341 613

E: brendon@vantagepointpartners.com.au



About Invion

Invion is a life-science company that is leading the global research and development of Photosoft™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the Photosoft™ technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by the Board of Invion Limited. For further information please contact investor@inviongroup.com.

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.